Xarelto Investigational Agent for Treatment and Prevention of Thromboembolic Events
Key Data:
Drug (Brand/Generic)
Xarelto (rivaroxaban)
Company/Licensee
Bayer and Johnson & Johnson
Therapy Class
Anticoagulant
Product Description
Selective inhibitor of coagulation factor Xa
Current Indication
Primary prevention and treatment of VTE following orthopaedic surgery
Market Sector
Cardiovascular
Development Status
Approved Europe; Phase III US
